Abstracts from the 21st International Congress on Thrombosis
The Start of a New Era for Antithrombotic Agents

Milan, Italy, July 6–9, 2010

Guest Editor
P.M. Mannucci, Milan, Italy
This publication has been produced by the Organizers of the 21st International Congress on Thrombosis
Contents

page

XII Foreword

Plenary Lectures

P1 Discovery of drugs in haemostasis and thrombosis by serendipity
M.M. Samama, France

P2 New targets in cardiovascular prevention: the identification of specific disease mechanisms
A. Maseri, Italy

Opening Symposium

Air pollution and thrombosis

P5 Air pollution, blood clotting and cardiovascular disease: evidence from epidemiological studies and impact on the population
A. Peters, Germany

P6 Beyond the DNA sequence: epigenetic mechanisms of prothrombotic air pollution effects
A. Baccarelli, Italy

P7 Inhaled particles and thrombosis: a clinical toxicology perspective
N.L. Mills, UK

Morning Lectures

P11 Hypercoagulability and thrombosis in sickle cell anemia and thalassemia
D. Varon, Israel

P12 Inflammation and atherothrombosis
E. Stroes, the Netherlands

P13 Leukocytosis as a thrombosis risk factor
T. Barbui, Italy

P15 Familial thrombophilia without a positive laboratory screening
J. Conard, France

P16 Haemotransfusion in coronary heart disease: friend or foe?
M. Lettino, Italy
P17 New antiplatelet agents: why they are badly needed by the cardiologist
P. A. Merlini, Italy

P18 Is aspirin less effective in patients with diabetes?
S. Coccheri, Italy

P19 Which antithrombotic and antiplatelet therapies in the ambulance for acute coronary syndrome?
M. Tubaro, Italy

P20 Biomarkers for the diagnosis of venous thromboembolism
A. Perrier, Switzerland

P21 Cerebral vein thrombosis
J. Ferro, Portugal

P22 Moderate hyperhomocysteinemia: marker or cause of a disease?
R. Abbate, Italy

P23 Pharmacoepidemiology of gastrointestinal bleeding complications of antiplatelet agents
A. Lanas, Spain

P24 Antithrombotic agents after vascular surgery
D. Bergqvist, Sweden

P25 What is new on the clinical aspects of fibrinolysis and thrombolysis?
J. A. Páramo, Spain

P26 Thromboprophylaxis in ‘minor’ orthopedic surgery
H. Bounameaux, Switzerland

P27 Highlights of the 5th International Conference on Thrombosis and Hemostasis Issues in Cancer (ICTHIC) 2010
A. Falanga, Italy

P28 A renaissance of the contact phase of blood coagulation.
U. Seligsohn, Israel

P29 News on the anticoagulant pathway of blood coagulation.
J. Corral, Spain

Debates

P32 Is it clinically useful to extend to the calf the ultrasound examination of deep leg veins? Yes/No
S.M. Schellong (Germany) vs G. Palareti (Italy)

P34 Variable antiplatelet response to thyenopiridines: should we use lab tests? Yes/No
J.F. Collet (France) vs B. Rocca (Italy)

P36 Thromboembolic pulmonary hypertension (CTEPH). Early surgery or watchful waiting?
A.M. D’Armini (Italy) vs F. Piovella (Italy)
Lectures

P41 Role of statins and exercise on vulnerable plaques
C. Liapis, Greece

P42 Thrombosis in neonates and children: What do we know - where to go?
U. Nowack-Göttl, Germany

P43 Adjunctive antithrombotic agents to amplify thrombolysis in ischemic stroke
J. Grotta, USA

P44 Discovery of quantitative traits loci for platelets
W. Ouwehand, UK

P45 The future of anticoagulant therapy
G. Agnelli, Italy

P46 The role of tissue factor in coronary artery disease
T.F Lüscher, Switzerland

Joint Symposium

Grupo Cooperativo Latinoamericano de Hemostasia y Trombosis (CLAHT) and Mediterranean League Against Thromboembolic Diseases (MLTD)

Advances in thrombosis

P49 What is new on the antiphospholipid syndrome criteria
R. Forastiero, Argentina

P50 Thrombotic complications in the treatment of patients with bleeding disorders
M. Mijares, Venezuela

P51 A multicentre randomised study of computer-assisted oral anticoagulant dosage versus medical staff dosage
L. Poller, UK

P52 Thrombosis prophylaxis in the ambulatory cancer patient: approaches to identifying the high risk patient
K. Bauer, USA

Symposia

Venous thromboembolism (VTE) in special clinical conditions: natural history

P53 Hormonal contraceptives, hormone-replacement therapy and thromboembolism
B. Brenner, Israel

P54 Venous thromboembolism (VTE) in the very elderly
A. Leizorovicz, France

P55 Venous thromboembolism (VTE) in the very young
M. Monreal, Spain
Advances in peripheral arterial disease

P56  Peripheral arterial disease in the spectrum of atherothrombosis
      G.D.O. Lowe, UK

P57  Asymptomatic peripheral arterial disease: impact on clinical practice
      F. Violi, Italy

P58  Antiplatelet treatment
      G. Y. Lip, UK

Genomewide association studies

P59  Stroke
      M. Breteler, the Netherlands

P60  Lessons from genome wide association studies in venous thrombosis
      P. Morange, France

P61  Mapping genes for plasma lipids and myocardial infarction in humans
      S. Kathiresan, USA

New anticoagulants: highlights on methodological issues

P62  Lack of standardization between antithrombotic trials in orthopedics: the scenario
      O.E. Dahl, Norway

P63  Methodological issues in trials assessing primary prophylaxis of venous thromboembolism
      C.M. Samama, France

P64  Make clinical studies in medical patients closer to usual hospital care
      J. Harenberg, Germany

P65  Guidelines on clinical testing of new antithrombotic drugs in surgical patients
      A.K. Kakkar, UK

Therapeutic advances in stroke

P66  Thrombolysis in acute stroke: present evidences and future perspectives
      D. Toni, Italy

P67  Secondary prevention of cerebral ischemia of arterial origin
      A. Algra, the Netherlands

P68  Secondary prevention of cardioembolic stroke: old and new drugs
      J. Ferro, Portugal

Platelets and inflammation

P69  Platelets and atherosclerosis
      M. Gawaz, Germany
P70  Platelets and allergic disorders  
P. Gresele, Italy

P71  Platelets, inflammation and acute coronary syndrome  
L. Badimon, Spain

Venous and arterial thromboembolism: an overlapping risk

P72  Clinical VTE and subsequent risk of arterial thrombotic events in non-provoked populations  
G.D.O. Lowe, UK

P73  Surgical triggering of venous and arterial thromboembolism: Immediate and long-term consequences  
O.E. Dahl, Norway

P74  Pregnancy and obstetric complications and the link to venous and arterial thrombosis  
I. Greer, UK

Special problems and strategies in anticoagulation

P75  Bridging strategies for interruption of anticoagulation for invasive procedures  
S. Schulman, Canada

P76  Antisense anticoagulant treatment  
M. Levi, the Netherlands

P77  Anticoagulant and thrombolytic treatment of portal vein and digestive tract thrombosis  
F. Leebeek, the Netherlands

Atrial fibrillation and heart failure as thrombotic disorders

P78  Atrial fibrillation as a thrombotic disease  
G. Y. Lip, UK

P79  Heart failure and thrombotic complications  
C. Torp-Pedersen, Denmark

P80  Heart failure as a prothrombotic state  
P.W. Kamphuisen, the Netherlands

The benefits and risks of low-dose aspirin in primary prevention of atherothrombosis

P82  Should aspirin be used for the primary prevention of vascular disease?  
C. Baigent, UK

P83  Aspirin for people with diabetes: current evidence and ongoing trials.  
J. Armitage, UK

P84  Ongoing trials on aspirin for primary prevention: will they deliver?  
G. Tognoni, Italy
Long-term complications of venous thromboembolism

P85 The optimal duration of anticoagulant therapy in patients with venous thromboembolism
P. Prandoni, Italy

P86 Long-term complications of venous thromboembolism
S. Kahn, Canada

P87 Advances in understanding the pathogenesis of chronic thromboembolic pulmonary hypertension
I. Lang, Austria

Dietary habits and cardiovascular risk

P88 Is the evidence from observational studies sufficient to state that Mediterranean diet reduces CV risk?
A. Kafatos, Greece

P89 Alcohol and cardiovascular risk: is there a window for benefits?
A. Di Castelnuovo, Italy

P90 Food and health: is inflammation the round-about?
H. Schröder, Spain

Satellite

Thrombotic microangiopathies

P93 The genetic base of congenital thrombotic thrombocytopenic purpura (TTP)
F. Peyvandi, Italy

P94 New therapies in acquired TTP
M. Scully, UK

P95 New diagnostic and prognostic aspects of acquired TTP
J. Kremer-Hovinga, Switzerland

P96 Rethinking thrombotic microangiopathies
G. Remuzzi, Italy

New perspectives in thrombosis research

P97 Complete deficiency of ADAMTS13 is sufficient to cause TTP in non-human primates
H.B. Feys, N. Vandeputte, J. Roodt, S. Lamprecht,
W.J. van Rensburg, V.J. Louw, P.N. Badenhorst,
H. Deckmyn, K. Vanhoorelbeke, Belgium and South Africa

P98 Aspirin resistance: myth or reality?
L. Muszbek, Z. Bereczky, E. Kovács, É. Katona, L. Balogh, N.
Homoródi, I. Édes, Hungary

P99 Environment and life style: can they affect the response to antiplatelet agents?
G. de Gaetano, C. Cerletti, Italy

P100 Arterial thrombosis in antiphospholipid syndrome
J. Musial, J. Swadzba, A. Matyja-Bednarczyk, T. Iwaniec, Poland
Current trends in the management and prophylaxis of venous thromboembolic disease

P101  The epidemiology of venous thromboembolism and experience with its management in Italy
W. Ageno, Italy

P102  The burden of venous thromboembolism in the hospital setting
A. T. Cohen, UK

P104  What can ongoing clinical trials of anticoagulants demonstrate?
H. R. Büller, the Netherlands

P105  Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement: the RECORD study program
L. Borris, Denmark

Thrombosis and antithrombotic therapy: what have we learnt in the low-molecular-weight heparin era?

P106  Thrombosis and antithrombotic therapy: how we currently use LMWHs
A. K. Kakkar, UK

P107  Recommendations for the preparation of biosimilar LMWHs according the ISTH SSC compared to FDA and EMEA views
J. Harenberg, Germany

P108  Biostatistical requirements for development of biosimilar LMWHs
P. Mismetti, France

Xa inhibition in the whole spectrum of venous thromboembolism: new insights

P109  Superficial vein thrombosis (SVT): recent epidemiology data
A. Leizorovicz, France

P110  Pharmacological treatment of SVT: what is the evidence?
H. Decousus, France

P111  Pharmacological management of deep vein thrombosis and pulmonary embolism
H. R. Büller, Netherlands

P112  SVT management guidelines
K. Bauer, USA

Heparin induced thrombocytopenia (HIT): diagnosis and treatment

P113  HIT: pathophysiology, incidence and guidelines
A. Greinacher, Germany

P114  Laboratory aspects in HIT diagnosis: current status
I. Elalamy, France
Clinical aspects and challenges in patient management
G. Palareti, Italy

Transforming the management of venous and arterial thrombosis

Venous and arterial thromboembolism
the causes and consequences
W. Ageno, Italy

Primary prevention of VTE after hip or knee arthroplasty - experience with dabigatran etexilate
B.I. Eriksson, Sweden

New developments in the treatment of acute VTE
P. Mismetti, France

Stroke prevention in atrial fibrillation – changing the paradigm?
R. de Caterina, Italy

Advancing the field of anticoagulation:
oral factor Xa inhibitors

Pharmacology of the new oral anticoagulants
J.W.A. Eikelboom, Canada

Recent trials of oral factor Xa inhibitors
in orthopaedic surgery
M.R. Lassen, Denmark

Future perspectives in oral anticoagulation
R. de Caterina, Italy

Focus on thrombin receptor antagonists
as antiplatelet agents

Limitations of currently available antiplatelets drugs
C. Patrono, Italy

Thrombin receptor antagonist as a novel approach
for the treatment of atherothrombosis
G. Ambrosio, Italy

The use of LMWHs in special clinical settings

Extension of thromboprophylaxis after surgery for cancer
P. Prandoni, Italy

Management of LMWHs in renal impairment and elderly patients
S. Rico, Spain

Prevention of VTE during pregnancy
A. Santamaria Ortiz, Spain

Optimizing antiplatelet therapy:
insight from large outcomes trials
D. Ardissino, Italy
P130 High on-treatment platelet reactivity as a risk factor for stent thrombosis
N.J. Breet, C.H. Hackeng, the Netherlands

Oral Presentations
A1 Pulmonary embolism
A2 Pregnancy and thrombosis
A4 Hematological disorders and thrombosis
A6 Mechanisms of Thrombosis 1
A8 Coronary artery disease
A10 New anticoagulants 1
A12 Clinical aspects of venous thromboembolism 1
A14 Thrombosis issues in internal medicine 1
A15 Ischemic stroke / atrial fibrillation
A17 Mechanisms of thrombosis 2
A19 New anticoagulants 2
A21 New and old predictors of venous thromboembolism
A23 Thrombosis issues in internal medicine and pediatrics 2
A24 Inherited Thrombophilia
A26 Clinical aspects of venous thromboembolism 2

Posters
A29 Clinical aspects of thrombosis
A42 Diagnostic and laboratory methods in thrombosis
A55 Inherited and acquired thrombophilia
A64 Cerebrovascular and peripheral atherothrombosis
A75 Pregnancy, hormones and thrombosis
A83 Mechanisms of thrombosis
A93 New anticoagulants
A100 Fibrinolysis and thrombolysis
A103 Cancer and thrombosis
A109 Atrial fibrillation
A111 Miscellanea
A115 Thrombosis risk factors
A126 Coronary artery disease
A133 Traditional anticoagulants
A145 Antiplatelet agents
A151 Hematological disorders and thrombosis

A159 Read by Title
A179 Index of Authors
Foreword

Pier Mannuccio Mannucci

Together with the members of the various Committees that have tremendously helped me (Executive Committee, International Committee, Advisory Committee and the Mediterranean League Council), I present you this Supplement of Pathophysiology of Thrombosis and Haemostasis, which contains the abstracts of the 21st International Thrombosis Congress, which I am organizing on behalf of the Mediterranean League against Thromboembolic Diseases.

I must admit that our main problem was one of abundance. We received as many as 643 submitted abstracts from 57 countries and the 5 continents: a record in the history of the MLTD Congresses! This abundance was not anticipated (only 255 abstracts were submitted for the 20th Congress in Athens two years ago). Hence, we have originally allotted a too limited space to oral communications and posters, by giving most of the space to invited Symposia, Lectures and Debates.

Each submitted abstract was evaluated by at least 3 reviewers and their ranking was the basis for the choice of their presentation as oral communications (only 14%) or poster.

Having said this as a preamble, we hope that this Book of Abstracts is satisfactory. The main topics are the new anticoagulant and antiplatelet agents, and venous thromboembolism prevails among the three most frequent thromboembolic diseases, even though coronary artery and cerebrovascular diseases are also well featured in the abstracts.

The Satellite events organized in collaboration with the pharmaceutical industry feature new drugs and new reagents and contribute substantially to the scientific quality of this publication, at this time of rapidly expanding availability of new weapons in the fight against thrombosis.

Finally, I want to express my thanks and gratitude to Silvia Malosio and Viviana Quaroni, who did a monumental job in collecting the abstracts published in this Supplement of Pathophysiology of Haemostasis and Thrombosis, the official Journal of the League.

Pier Mannuccio Mannucci
Guest Editor